Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 1,002 put options on the company.

RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on February 4 and set a ...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and ...

Maravai LifeSciences (NASDAQ:MRVI) said on Wednesday that based on preliminary year-end results, the company expects to report total 2024 revenue near the mid-point of the previously announced ...

Maravai LifeSciences Holdings, Inc. announced that it expects total revenue for 2024 to align with its previous guidance range of $255 million to $265 million based on preliminary year-end results ...

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support ...

TriLink BioTechnologies, a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has signed a ...

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...